Compounds > n-(4,6-dimethyl-2-pyridinyl)benzamide
Page last updated: 2024-12-07

n-(4,6-dimethyl-2-pyridinyl)benzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID124524
CHEMBL ID152710
SCHEMBL ID3362301
MeSH IDM0162194

Synonyms (11)

Synonym
n-(4,6-dimethyl-2-pyridinyl)benzamide
benzamide, n-(4,6-dimethyl-2-pyridinyl)-
STK471705
n-(4,6-dimethylpyridin-2-yl)benzamide
CHEMBL152710
AKOS003287825
94843-50-2
SCHEMBL3362301
benzamide,n-(4,6-dimethyl-2-pyridinyl)-
DTXSID70241640
CS-0367837
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID117623Motility against number of interrupted beams in 1 hour in naive mice by 13 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID117614Antipsychotic effect was tested against motility scores in naive mice at a control value of 8151985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID117615Antipsychotic effect was tested against motility scores in reserpinized mice at a control value of 111985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID117618Motility of the Compound was tested against number of interrupted beams in 1 hour in reserpine treated mice by 8 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID180427Compound Evaluated for the homovanillic acid levels of rats corpus striata by 12 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID180428Compound Evaluated for the homovanillic acid levels of rats limbic system by 12 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID117619Motility of the Compound was tested against number of interrupted beams in 1 hr in reserpine & apomorphine treated mice by 14 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (50.00)18.7374
1990's2 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		1.9910clonidine;
imidazoline
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		1.9710aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		1.9610benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
sultopride
[no description available]		1.9610salicylamides
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		1.9810prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
ConditionIndicatedRelationship StrengthStudiesTrials
Brain Swelling
[description not available]		02.6730
Innate Inflammatory Response
[description not available]		01.9910
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		02.6730
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9910
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710